Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 7/20 | 0.53 |
| ▸ | RARG | P13631 | 7/20 | 0.53 |
| ▸ | RARA | P10276 | 4/20 | 0.53 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 10/20 | 0.41 |
| ▸ | RXRB | P28702 | 8/20 | 0.41 |
| ▸ | RXRG | P48443 | 6/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9483828 | 0.89 | RARB (0.63) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL16905203 | 0.88 | PGR (0.42) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL10515704 | 0.81 | RARB (0.58) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL10515701 | 0.81 | RARB (0.58) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL26892628 | 0.81 | KDM1A (0.57) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL2223568 | 0.80 | RARB (0.53) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL16905204 | 0.80 | KDM1A (0.44) | KDM1ADRD2DRD3PNMT | |
| SCHEMBL3838094 | 0.80 | RARB (0.57) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19342919 | 0.79 | CYP3A4 (0.49) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL9484150 | 0.79 | RXRA (0.42) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109206381-B | A method for preparing compound intermediate for regulating activity of cannabinoid receptor | 珠海润都制药股份有限公司 | 2021-10-08 | — | — | CN | disclosed |
| US-20170170413-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20170170413-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-06-15 | — | — | US | disclosed |
| WO-2015117718-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | WO | disclosed |
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| EP-2513066-A1 | SPHINGOSINE KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011082732-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
| US-5475017-A | Skin disorders, antitumor agents; side effect reduction | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | disclosed |
| EP-0382077-B1 | Diaryl-substituted heterocyclic compound, its preparation and medicaments and cosmetics made thereof | BASF AG (DE) | 1995-05-17 | — | — | EP | disclosed |
| US-5338749-A | Treating rheumatic or arthritic disorders | BASF AKTIENGESELLSCHAFT (DE) | 1994-08-16 | — | — | US | disclosed |
| US-5206242-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-04-27 | — | — | US | disclosed |
| US-5196532-A | Treatment of skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-23 | — | — | US | disclosed |
| US-5061705-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1991-10-29 | — | — | US | disclosed |
| EP-0382077-A2 | Diaryl-substituted heterocyclic compound, its preparation and medicaments and cosmetics made thereof | BASF Aktiengesellschaft (DE) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170170413-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | RARB 3717/4885RARG 3452/4885RARA 3284/4885 |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, S1PR3, SPHK2 | RARB 4278/4885RARG 2466/4885RARA 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.